Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanisms of Huazhuojiedu Decoction to Treat Chronic Atrophic Gastritis

Background. Chronic atrophic gastritis (CAG) is an important stage in the normal gastric mucosa’s transformation into gastric cancer. Huazhuojiedu decoction (HZJD), a Chinese herbal preparation, has proven clinically effective to treat CAG. However, few studies have explored the mechanism of HZJD in...

Full description

Bibliographic Details
Main Authors: Xinyu Hao, Yu Liu, Pingping Zhou, Qian Jiang, Zeqi Yang, Miaochan Xu, Shaowei Liu, Shixiong Zhang, Yangang Wang
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Evidence-Based Complementary and Alternative Medicine
Online Access:http://dx.doi.org/10.1155/2020/2638362
id doaj-f87e0a4fd43e4fefb599e120a9ec159e
record_format Article
spelling doaj-f87e0a4fd43e4fefb599e120a9ec159e2020-12-21T11:41:29ZengHindawi LimitedEvidence-Based Complementary and Alternative Medicine1741-427X1741-42882020-01-01202010.1155/2020/26383622638362Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanisms of Huazhuojiedu Decoction to Treat Chronic Atrophic GastritisXinyu Hao0Yu Liu1Pingping Zhou2Qian Jiang3Zeqi Yang4Miaochan Xu5Shaowei Liu6Shixiong Zhang7Yangang Wang8Hebei University of Chinese Medicine, Shijiazhuang 050200, ChinaHebei University of Chinese Medicine, Shijiazhuang 050200, ChinaHebei University of Chinese Medicine, Shijiazhuang 050200, ChinaThe First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050011, ChinaHebei University of Chinese Medicine, Shijiazhuang 050200, ChinaHebei University of Chinese Medicine, Shijiazhuang 050200, ChinaHebei University of Chinese Medicine, Shijiazhuang 050200, ChinaHebei University of Chinese Medicine, Shijiazhuang 050200, ChinaThe First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050011, ChinaBackground. Chronic atrophic gastritis (CAG) is an important stage in the normal gastric mucosa’s transformation into gastric cancer. Huazhuojiedu decoction (HZJD), a Chinese herbal preparation, has proven clinically effective to treat CAG. However, few studies have explored the mechanism of HZJD in CAG treatment. Purpose. This study aimed to shed light on the mechanisms underlying HZJD decoction CAG treatment using a network pharmacology approach and experimental validation. Methods. The active components of HZJD decoction were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. Their targets were predicted through the SwissTargetPrediction database. Disease targets were screened using the GeneCards database. The disease and drug prediction targets were intersected to select the common potential therapeutic targets, which then were input into the Search Tool for the Retrieval of Interacting Genes to build a protein-protein interaction network. The “herb-compound-target-disease” and the “herb-target-pathway” network diagrams were constructed in Cytoscape 3.3.0. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of effective targets were performed using the Database for Annotation, Visualization, and Integrated Discovery. Finally, the core targets were preliminarily verified by CAG rat model. The gastric mucosa’s histopathological changes were observed via hematoxylin-eosin staining. The expressions of MAPK1, AKT1, TNF, VEGFA, and EGFR were detected by western blot and quantitative real-time reverse transcription-polymerase chain reaction. Results. A total of 155 nodes, including 20 putative targets of HZJD decoction, were selected as core hubs based on topological importance and were closely associated with the regulation of cell proliferation, apoptotic process, and cancer-related pathways (AKT1, TNF, VEGFA, and EGFR) in CAG. Further animal experiments showed that the expression of AKT1 in CAG rats was significantly increased, which was suppressed by HZJD decoction. TNF and VEGFA expression increased in the model group, but did not change in the HZJD group. MAPK1 and EGFR expression showed no significant differences among control, model, and HZJD groups. Conclusion. Taken together, the results suggest that the components of HZJD decoction can alleviate and prevent the severity of gastric precancerous lesions via AKT1 inhibition in CAG.http://dx.doi.org/10.1155/2020/2638362
collection DOAJ
language English
format Article
sources DOAJ
author Xinyu Hao
Yu Liu
Pingping Zhou
Qian Jiang
Zeqi Yang
Miaochan Xu
Shaowei Liu
Shixiong Zhang
Yangang Wang
spellingShingle Xinyu Hao
Yu Liu
Pingping Zhou
Qian Jiang
Zeqi Yang
Miaochan Xu
Shaowei Liu
Shixiong Zhang
Yangang Wang
Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanisms of Huazhuojiedu Decoction to Treat Chronic Atrophic Gastritis
Evidence-Based Complementary and Alternative Medicine
author_facet Xinyu Hao
Yu Liu
Pingping Zhou
Qian Jiang
Zeqi Yang
Miaochan Xu
Shaowei Liu
Shixiong Zhang
Yangang Wang
author_sort Xinyu Hao
title Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanisms of Huazhuojiedu Decoction to Treat Chronic Atrophic Gastritis
title_short Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanisms of Huazhuojiedu Decoction to Treat Chronic Atrophic Gastritis
title_full Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanisms of Huazhuojiedu Decoction to Treat Chronic Atrophic Gastritis
title_fullStr Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanisms of Huazhuojiedu Decoction to Treat Chronic Atrophic Gastritis
title_full_unstemmed Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanisms of Huazhuojiedu Decoction to Treat Chronic Atrophic Gastritis
title_sort integrating network pharmacology and experimental validation to investigate the mechanisms of huazhuojiedu decoction to treat chronic atrophic gastritis
publisher Hindawi Limited
series Evidence-Based Complementary and Alternative Medicine
issn 1741-427X
1741-4288
publishDate 2020-01-01
description Background. Chronic atrophic gastritis (CAG) is an important stage in the normal gastric mucosa’s transformation into gastric cancer. Huazhuojiedu decoction (HZJD), a Chinese herbal preparation, has proven clinically effective to treat CAG. However, few studies have explored the mechanism of HZJD in CAG treatment. Purpose. This study aimed to shed light on the mechanisms underlying HZJD decoction CAG treatment using a network pharmacology approach and experimental validation. Methods. The active components of HZJD decoction were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. Their targets were predicted through the SwissTargetPrediction database. Disease targets were screened using the GeneCards database. The disease and drug prediction targets were intersected to select the common potential therapeutic targets, which then were input into the Search Tool for the Retrieval of Interacting Genes to build a protein-protein interaction network. The “herb-compound-target-disease” and the “herb-target-pathway” network diagrams were constructed in Cytoscape 3.3.0. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of effective targets were performed using the Database for Annotation, Visualization, and Integrated Discovery. Finally, the core targets were preliminarily verified by CAG rat model. The gastric mucosa’s histopathological changes were observed via hematoxylin-eosin staining. The expressions of MAPK1, AKT1, TNF, VEGFA, and EGFR were detected by western blot and quantitative real-time reverse transcription-polymerase chain reaction. Results. A total of 155 nodes, including 20 putative targets of HZJD decoction, were selected as core hubs based on topological importance and were closely associated with the regulation of cell proliferation, apoptotic process, and cancer-related pathways (AKT1, TNF, VEGFA, and EGFR) in CAG. Further animal experiments showed that the expression of AKT1 in CAG rats was significantly increased, which was suppressed by HZJD decoction. TNF and VEGFA expression increased in the model group, but did not change in the HZJD group. MAPK1 and EGFR expression showed no significant differences among control, model, and HZJD groups. Conclusion. Taken together, the results suggest that the components of HZJD decoction can alleviate and prevent the severity of gastric precancerous lesions via AKT1 inhibition in CAG.
url http://dx.doi.org/10.1155/2020/2638362
work_keys_str_mv AT xinyuhao integratingnetworkpharmacologyandexperimentalvalidationtoinvestigatethemechanismsofhuazhuojiedudecoctiontotreatchronicatrophicgastritis
AT yuliu integratingnetworkpharmacologyandexperimentalvalidationtoinvestigatethemechanismsofhuazhuojiedudecoctiontotreatchronicatrophicgastritis
AT pingpingzhou integratingnetworkpharmacologyandexperimentalvalidationtoinvestigatethemechanismsofhuazhuojiedudecoctiontotreatchronicatrophicgastritis
AT qianjiang integratingnetworkpharmacologyandexperimentalvalidationtoinvestigatethemechanismsofhuazhuojiedudecoctiontotreatchronicatrophicgastritis
AT zeqiyang integratingnetworkpharmacologyandexperimentalvalidationtoinvestigatethemechanismsofhuazhuojiedudecoctiontotreatchronicatrophicgastritis
AT miaochanxu integratingnetworkpharmacologyandexperimentalvalidationtoinvestigatethemechanismsofhuazhuojiedudecoctiontotreatchronicatrophicgastritis
AT shaoweiliu integratingnetworkpharmacologyandexperimentalvalidationtoinvestigatethemechanismsofhuazhuojiedudecoctiontotreatchronicatrophicgastritis
AT shixiongzhang integratingnetworkpharmacologyandexperimentalvalidationtoinvestigatethemechanismsofhuazhuojiedudecoctiontotreatchronicatrophicgastritis
AT yangangwang integratingnetworkpharmacologyandexperimentalvalidationtoinvestigatethemechanismsofhuazhuojiedudecoctiontotreatchronicatrophicgastritis
_version_ 1714988422045630464